Back

Tumor microenvironment signature associated with morphology in systemic ALK-positive anaplastic large cell lymphoma

Bessiere, C.; Babin, L.; Dailhau, S.; Gaulard, P.; Pyronnet, S.; Meggetto, F.; Lamant, L.

2026-01-20 cancer biology
10.64898/2026.01.20.700117 bioRxiv
Show abstract

Peripheral T-cell lymphomas (PTCL) are heterogeneous entities whose tumoral microenvironment (TME) may influence disease phenotype and outcome. To dissect their immune and stromal composition, we used two complementary algorithms, CIBERSORTx and MCP-counter, on Affymetrix data from 255 patients whole-tissue biopsies, including 78 systemic anaplastic large cell lymphomas (ALCL). Clustering based on inferred cell proportions revealed a clear separation between ALCL and other PTCL subtypes, including angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS). ALCL-enriched clusters were characterised by granulocytes and macrophages lineages, mast cells, NK cells, memory CD4+ T-cells, as well as fibroblast and endothelial signatures, whereas as expected, AITL cluster was enriched for T-follicular helper cells, B-cells and macrophages. Finally, we focused on 66 ALCL cases with relapse risk and morphological subtype clinical annotations. Distinct TME features enriched in M1 macrophages and monocytes were associated with adverse outcomes and non-common morphological variants. Transcriptomic analyses of mononuclear phagocytes across Affymetrix and RNAseq datasets confirmed distinct clustering according to cell morphology. These analyses identified potential biomarkers associated with uncommon variants and absent from ALK+ ALCL cell lines, confirming their TME origin. Macrophage- and monocyte-related signatures emerged as key contributors in ALK+ ALCL patients heterogeneity, linking TME patterns to tumor morphology and prognosis. These signatures may serve as biomarkers for patient risk stratification and guide the development of targeted therapies.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Leukemia
39 papers in training set
Top 0.1%
10.3%
2
Nature Communications
4913 papers in training set
Top 18%
10.0%
3
Blood Advances
54 papers in training set
Top 0.2%
7.1%
4
Blood
67 papers in training set
Top 0.2%
6.7%
5
Cancer Immunology Research
34 papers in training set
Top 0.1%
3.6%
6
Genome Medicine
154 papers in training set
Top 2%
3.6%
7
eLife
5422 papers in training set
Top 26%
3.6%
8
Cancers
200 papers in training set
Top 2%
3.6%
9
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.4%
3.6%
50% of probability mass above
10
Cell Reports Medicine
140 papers in training set
Top 2%
2.6%
11
OncoImmunology
22 papers in training set
Top 0.1%
2.1%
12
Acta Neuropathologica
51 papers in training set
Top 0.5%
2.1%
13
Frontiers in Immunology
586 papers in training set
Top 4%
1.9%
14
Clinical Cancer Research
58 papers in training set
Top 1%
1.7%
15
Cancer Research
116 papers in training set
Top 2%
1.7%
16
Cancer Discovery
61 papers in training set
Top 1%
1.7%
17
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.5%
18
Nature Cancer
35 papers in training set
Top 0.8%
1.5%
19
Nature Cell Biology
99 papers in training set
Top 3%
1.3%
20
Cell Reports
1338 papers in training set
Top 27%
1.3%
21
EBioMedicine
39 papers in training set
Top 0.6%
1.2%
22
Molecular Oncology
50 papers in training set
Top 0.6%
1.2%
23
Journal of Clinical Investigation
164 papers in training set
Top 5%
1.1%
24
Frontiers in Oncology
95 papers in training set
Top 3%
0.9%
25
Neuro-Oncology
30 papers in training set
Top 0.6%
0.9%
26
PLOS Computational Biology
1633 papers in training set
Top 22%
0.9%
27
Modern Pathology
21 papers in training set
Top 0.3%
0.9%
28
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.2%
0.9%
29
Laboratory Investigation
13 papers in training set
Top 0.2%
0.8%
30
Scientific Reports
3102 papers in training set
Top 75%
0.7%